Oxoisoaporphine alkaloid derivative 8-1 reduces Aβ 1-42 secretion and toxicity in human cell and Caenorhabditis elegans models of Alzheimer's disease

• Published in: Neurochemistry international Vol. 108; pp. 157 - 168
• Main Authors: Huang, Liyingzi, Luo, Yunfeng, Pu, Zhijun, Kong, Xianghui, Fu, Xiang, Xing, Huanhuan, Wei, Shenqi, Chen, Wei, Tang, Huang
• Format: Journal Article
• Language: English
• Published: England 01.09.2017
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Amyloid beta-Peptides - antagonists & inhibitors; Amyloid beta-Peptides - secretion; Amyloid beta-Peptides - toxicity; Animals; Animals, Genetically Modified; Apomorphine - analogs & derivatives; Apomorphine - chemistry; Apomorphine - pharmacology; Apomorphine - therapeutic use; Benzodioxoles - pharmacology; Benzodioxoles - therapeutic use; Caenorhabditis elegans; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - physiology; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Oxidative Stress - drug effects; Oxidative Stress - physiology; Peptide Fragments - antagonists & inhibitors; Peptide Fragments - chemistry; Peptide Fragments - pharmacology; Peptide Fragments - secretion; Peptide Fragments - therapeutic use; Peptide Fragments - toxicity; Phthalazines - pharmacology; Phthalazines - therapeutic use; Caenorhabditis elegans; Aβ(1-42); Alzheimer's disease; Oxoisoaporphine alkaloid derivative; SH-SY5Y cell

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease and a growing health problem worldwide. Because the drugs currently used to treat AD have certain drawbacks such as single targeting, there is a need to develop novel multi-target compounds, among which oxoisoaporphine alkal...